These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 26350371)

  • 1. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.
    Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
    Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
    World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
    Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma.
    Thomas RM; Truty MJ; Kim M; Kang Y; Zhang R; Chatterjee D; Katz MH; Fleming JB
    Ann Surg Oncol; 2015; 22(6):1884-92. PubMed ID: 25404477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy.
    Swords DS; Francis SR; Lloyd S; Garrido-Laguna I; Mulvihill SJ; Gruhl JD; Christensen MC; Stoddard GJ; Firpo MA; Scaife CL
    J Gastrointest Surg; 2019 Jul; 23(7):1401-1413. PubMed ID: 30187332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma.
    Matsumoto I; Tanaka M; Shirakawa S; Shinzeki M; Toyama H; Asari S; Goto T; Yamashita H; Ishida J; Ajiki T; Fukumoto T; Shimokawa M; Ku Y
    Ann Surg Oncol; 2015 Jul; 22(7):2408-15. PubMed ID: 25487967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse oncologic effects of intraoperative transfusion during pancreatectomy for left-sided pancreatic cancer: the need for strict transfusion policy.
    Hwang HK; Jung MJ; Lee SH; Kang CM; Lee WJ
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):497-507. PubMed ID: 27295957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resected pancreatic adenocarcinoma: An Asian institution's experience.
    Ng KYY; Chow EWX; Jiang B; Lim C; Goh BKP; Lee SY; Teo JY; Tan DMY; Cheow PC; Ooi LLPJ; Chow PKH; Lee JJX; Kam JH; Koh YX; Jeyaraj PR; Tan EK; Choo SP; Chan CY; Chung AYF; Tai D
    Cancer Rep (Hoboken); 2021 Oct; 4(5):e1393. PubMed ID: 33939335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.
    Serrano PE; Cleary SP; Dhani N; Kim PT; Greig PD; Leung K; Moulton CA; Gallinger S; Wei AC
    Ann Surg Oncol; 2015 Apr; 22(4):1160-7. PubMed ID: 25348784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Preoperative Biliary Drainage on Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma: A Multicenter Observational Study.
    Uemura K; Murakami Y; Satoi S; Sho M; Motoi F; Kawai M; Matsumoto I; Honda G; Kurata M; Yanagimoto H; Nishiwada S; Fukumoto T; Unno M; Yamaue H
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1238-46. PubMed ID: 26014151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy.
    Newhook TE; Prakash LR; Soliz J; Hancher-Hodges S; Speer BB; Wilks JA; Bruno ML; Dewhurst WL; Arvide EM; Maxwell JE; Ikoma N; Kim MP; Lee JE; Katz MHG; Tzeng CD
    J Surg Oncol; 2021 Dec; 124(8):1381-1389. PubMed ID: 34398988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
    Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
    J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
    Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
    Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
    Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.